| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRA2b |
| Uniprot No | P62995 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 120-199aa |
| 氨基酸序列 | LGVFGLSLYTTERDLREVFSKYGPIADVSIVYDQQSRRSRGFAFVYFENV DDAKEAKERANGMELDGRRIRVDFSITKRP |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TRA2b重组蛋白的3篇参考文献及其摘要：
1. **《Cloning and Functional Analysis of Recombinant TRA2b in mRNA Splicing Regulation》**
- 作者：H. Suzuki 等
- 摘要：研究通过克隆人源TRA2b基因并在大肠杆菌中表达重组蛋白，验证了其结合特定RNA序列的能力，证实其在体外剪接实验中对选择性剪接的关键调控作用。
2. **《Aberrant TRA2b Expression Promotes Cancer Progression via Alternative Splicing》**
- 作者：K. Nakata 等
- 摘要：利用重组TRA2b蛋白进行体外细胞实验，发现其过表达通过改变癌症相关基因(如BCL2L1)的剪接模式，促进肿瘤细胞存活和侵袭，提示其在癌症治疗中的潜在靶点价值。
3. **《Structural Insights into TRA2b RNA Recognition Motif by X-ray Crystallography》**
- 作者：T. Sato 等
- 摘要：通过X射线晶体学解析重组TRA2b蛋白的RNA结合结构域，揭示了其与靶RNA相互作用的分子机制，为设计调控TRA2b功能的化合物提供了结构基础。
这些研究涵盖了TRA2b重组蛋白的功能验证、病理机制及结构解析，展示了其在基础研究和应用中的重要性。
TRA2b (Transformer-2 Beta), also known as TRA2B or SFRS10. is a serine/arginine-rich (SR) protein family member involved in pre-mRNA splicing, a critical step in eukaryotic gene expression. It regulates alternative splicing by binding to specific RNA sequences, such as exonic splicing enhancers (ESEs), to promote the inclusion or exclusion of exons during mRNA maturation. This process generates transcript diversity, allowing a single gene to encode multiple protein isoforms with distinct functions. TRA2b is particularly known for its role in splicing events related to cell cycle regulation, apoptosis, and neuronal development.
Structurally, TRA2b contains an RNA recognition motif (RRM) that mediates interactions with target RNAs and a C-terminal RS domain rich in serine/arginine dipeptides, which facilitates protein-protein interactions within the spliceosome. Its activity is modulated by post-translational modifications, including phosphorylation, which influences subcellular localization and splicing efficiency.
Recombinant TRA2b protein is engineered for in vitro studies to dissect its splicing mechanisms, RNA-binding specificity, and interactions with spliceosomal components. It is produced using expression systems (e.g., E. coli or mammalian cells) with tags for purification and detection. Researchers use it to study diseases linked to splicing defects, such as cancer, where TRA2b overexpression correlates with tumor progression by dysregulating splicing of oncogenes (e.g., BCL2L1. CDC25B). It also has implications in neurodegenerative disorders, where aberrant splicing contributes to pathologies like Alzheimer’s disease.
Therapeutic strategies targeting TRA2b are emerging, including antisense oligonucleotides or small molecules to correct pathological splicing events. Its recombinant form thus serves as a tool for drug discovery and functional genomics.
×
